TICKERNERD
Menu
IOVAIOVAHealthcare · Biotechnology

IOVA Stock Forecast: Iovance Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$14
−0.42% on the day

The 10 Wall Street analysts covering Iovance Biotherapeutics, Inc. hold a median 12-month price target of $16 — +10.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 24 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$6.4B
Ticker Nerd rank
93/ 100
Median analyst target
$16
Analysts covering
10
Revenue$99.3M+65.7% y/y
Operating income−$51.9M
Net income−$47.3M
Free cash flow−$66.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.4%
1M
+38.2%
YTD
+415.8%
1Y
+542.9%
From 52W high
−5.2%
From 52W low
+677.9%
$2
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IOVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Iovance Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
93/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Quality
95
Value
92
Revisions
91
Growth
80
Accruals
44
Issuance
44
Volatility
36
Size
20

Momentum (99): The shares have been drifting up relative to others.

Volatility (36): The share price moves around a lot.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IOVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IOVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26IOVAHigh $20Median $16Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $7Median $16High $20

The green dot is the last close — the median target sits +10.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
13 Oct 2026BarclaysMaintainsOverweight$15 → $18
8 Oct 2026BairdMaintainsNeutral$6.00 → $11
30 Sept 2026Wells FargoMaintainsOverweight—
30 Sept 2026Wells FargoMaintainsOverweight$14 → $18
29 Sept 2026HC Wainwright & Co.MaintainsBuy—
29 Sept 2026HC Wainwright & Co.MaintainsBuy$9.00 → $20
24 Sept 2026Goldman SachsReinstatesBuy$15
17 Sept 2026BarclaysMaintainsOverweight—
17 Sept 2026BarclaysMaintainsOverweight$13 → $15
25 Aug 2026TD CowenMaintainsBuy—
25 Aug 2026TD CowenMaintainsBuy$7.00 → $10
20 Aug 2026UBSMaintainsNeutral$4.00 → $7.00
20 Aug 2026UBSMaintainsNeutral—
18 Aug 2026MizuhoMaintainsOutperform$10 → $11
18 Aug 2026MizuhoMaintainsOutperform—
7 Aug 2026BarclaysMaintainsOverweight—
7 Aug 2026BarclaysMaintainsOverweight$11 → $13
7 Aug 2026CitizensMaintainsMarket Outperform$5.00 → $8.00
7 Aug 2026CitizensMaintainsMarket Outperform—
8 May 2026Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IOVA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

IOVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Iovance Biotherapeutics, Inc. returned +542.9% against +14.3% for the S&P 500, dividends included.

IOVA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Jan 26Apr 26Jul 26Oct 26IOVAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IOVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
0
Fundamentals

Iovance Biotherapeutics, Inc. (IOVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.9×

Cheaper than 95% of US stocks

Price / sales
19.6×

Cheaper than 8% of US stocks

Price / book
8.7×

Cheaper than 10% of US stocks

EV / EBITDA
−23.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
65.7%

Higher than 89% of US stocks

Earnings growth (YoY)
65.7%

Higher than 79% of US stocks

Gross margin
56.1%

Higher than 69% of US stocks

Operating margin
−52.3%

Higher than 17% of US stocks

Net margin
−89.1%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−40.4%

Higher than 24% of US stocks

Return on assets
−20.3%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Iovance Biotherapeutics, Inc. (IOVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Iovance Biotherapeutics, Inc. has a market value of $6.4B and an enterprise value of $6.1B.

  • Revenue in the twelve months to 30 June 2026: $325.0M. The latest quarter grew 65.7% year on year.

  • Net income over the same four quarters: −$289.5M, a −89.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.73.

  • Free cash flow in the twelve months to 30 June 2026: −$296.4M.

  • Shares outstanding: 453.0M.

  • Trailing P/E: −12.9×; forward P/E: −72.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Iovance Biotherapeutics, Inc. employs 975 people — $333K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 26 Oct 2026

Data provided by Twelve Data

Peers

IOVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IOVAIovance Biotherapeutics, Inc.$6.4B93
RYTMRhythm Pharmaceuticals, Inc.$6.1B87
LGNDLigand Pharmaceuticals, Inc.$6.0B71
IMVTImmunovant, Inc.$5.7B39
MANEVeradermics, Inc.$5.7B3
PRAXPraxis Precision Medicines, Inc.$6.9B42
IONSIonis Pharmaceuticals, Inc.$7.1B39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Iovance Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IOVA news & analysis

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

GlobeNewsWire · 26 Oct 2026positive

Iovance reported that one-time lifileucel monotherapy achieved a physician-assessed confirmed objective response rate of 50% among the first eight evaluable patients in a pilot trial involving metastatic UPS and DDLPS. The responses were ongoing at the time of the oral presentation at ESMO Congress 2026.

Why it matters — The early trial findings provide IOVA watchers with clinical data on lifileucel in two difficult-to-treat soft tissue sarcomas.

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

GlobeNewsWire · 23 Oct 2026positive

Iovance reported final Phase 2 results for one-time lifileucel plus pembrolizumab in frontline advanced melanoma, showing a 62.5% confirmed objective response rate and 29.2% complete response rate. Median overall survival was not reached at 50.9 months of median follow-up; the data were presented at ESMO 2026.

Why it matters — The findings provide updated clinical data for the combination and reinforce the ongoing TILVANCE-301 Phase 3 trial.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks Investment Research · 20 Oct 2026neutral

Zacks Investment Research describes its Zacks Earnings ESP as a tool for finding stocks expected to beat quarterly earnings estimates. The excerpt does not provide Iovance-specific earnings information.

Why it matters — IOVA watchers may note the article’s earnings-estimate focus, but the excerpt gives no company-specific details about Iovance.

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

GlobeNewsWire · 19 Oct 2026positive

Iovance said it will present five abstracts from its TIL therapy platform at the ESMO Congress 2026, including two oral presentations of new clinical data in frontline advanced melanoma and previously treated soft tissue sarcomas. The congress is scheduled for October 23–27 in Madrid.

Why it matters — The presentations will highlight clinical data from Iovance’s TIL platform across solid tumors, including two disease settings described as new areas of focus.

Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And More

Seeking Alpha · 19 Oct 2026neutral

Seeking Alpha’s Undercovered Dozen featured Iovance Biotherapeutics among 12 lesser-covered stocks highlighted from the past week. The series presents articles intended to spark investment ideas and discussion about overlooked equities.

Why it matters — IOVA watchers may note the company was included in a curated roundup focused on lesser-covered stocks.

FAQ

Frequently asked questions about IOVA stock

What is the IOVA stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Iovance Biotherapeutics, Inc. have a median 12-month price target of $16, with estimates ranging from $7 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IOVA stock a buy right now?

Of the 10 analysts covering Iovance Biotherapeutics, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iovance Biotherapeutics, Inc. 93 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IOVA?

As at 24 Oct 2026, Iovance Biotherapeutics, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will IOVA stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +10.1% from the last close, and Ticker Nerd's factor model ranks Iovance Biotherapeutics, Inc. 93 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IOVA stock forecast for 2030?

No analyst covering Iovance Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $20 over the next 12 months.

How has IOVA stock performed over the past year?

Iovance Biotherapeutics, Inc. returned +542.9% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Iovance Biotherapeutics, Inc. do?

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer.

What is the latest news on IOVA?

The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026". Iovance reported that one-time lifileucel monotherapy achieved a physician-assessed confirmed objective response rate of 50% among the first eight evaluable patients in a pilot trial involving metastatic UPS and DDLPS. The responses were ongoing at the time of the oral presentation at ESMO Congress 2026.

Company

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor infiltrating lymphocyte, or TIL, cell therapies for cancer. Its current portfolio centers on Amtagvi, an individualized cell therapy used in advanced melanoma, and Proleukin, which supports the treatment regimen. The company also advances investigational TIL-based programs for other solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance Biotherapeutics operates as an oncology-focused cell therapy platform, combining manufacturing, clinical development, and commercialization capabilities to deliver personalized immunotherapies for patients with difficult-to-treat cancers. Headquartered in San Carlos, California, it plays a specialized role in the broader biopharmaceutical market by bringing autologous immune-cell therapies into routine clinical use.

CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D. · 975 employees · United States · https://www.iovance.com